Stabilized Poliovirus-Like Particles for Safe Vaccine Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current polio vaccines, particularly the live attenuated oral polio vaccine, pose risks due to the potential for vaccine-associated poliomyelitis and reversion to a transmissible phenotype, and the production of inactivated polio vaccine requires wild-type polioviruses that are hazardous and difficult to handle safely at large scales.
Innovation Solution
Development of stable poliovirus-like particles (VLPs) through genetic modifications that stabilize the capsid, eliminating the need for infectious virus production and reducing safety concerns, by introducing specific mutations at defined residues in the capsid proteins to enhance stability and immunogenicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If live attenuated oral polio vaccine is used, then vaccination coverage and immunity are improved, but risk of vaccine-associated poliomyelitis and reversion to transmissible phenotype increases
Solution Approach 1:
The patent creates virus-like particles that copy the immunogenic structure of live poliovirus without containing infectious genetic material. The VLPs replicate the capsid protein arrangement and antigenic determinants of natural poliovirus, enabling immune system recognition and antibody production while eliminating the replication and reversion risks inherent in live attenuated vaccines.
Solution Approach 2:
The patent extracts the essential immunogenic components (capsid proteins VP1, VP2, VP3) from the complete infectious virus structure. By producing only the structural proteins that elicit protective immunity while removing the RNA genome and replication machinery, the vaccine maintains effectiveness while eliminating harmful effects of viral replication.
2Reliability
If inactivated polio vaccine is produced using wild type polioviruses, then vaccine immunogenicity is improved, but safety hazards and containment difficulty increase
Solution Approach 1:
The patent produces vaccine antigens by expressing capsid protein genes in safe cell cultures rather than growing live wild type virus. The VLPs generated contain the same immunogenic capsid structures needed for protective immunity but are produced through recombinant expression of structural genes only, eliminating the need to handle hazardous live virus during manufacturing.
Solution Approach 2:
The patent uses recombinant DNA technology as an intermediary approach. Instead of directly manipulating and inactivating live virus, the system uses cloned capsid gene sequences expressed in host cells to produce the viral antigens. This intermediary method allows production of immunogenic material without requiring propagation of hazardous wild type poliovirus.
3Reliability
If stable poliovirus-like particles are produced through genetic modifications, then safety and stability are improved, but manufacturing complexity increases
Solution Approach 1:
The patent introduces specific point mutations in the capsid protein coding sequences (e.g., in VP1, VP2, or VP3 genes) that stabilize the folded structure and assembly of VLPs. These parameter changes at the molecular level enhance thermal and structural stability of the particles, improving vaccine shelf-life and robustness without requiring complex manufacturing processes.
Data Source
AI summary
The invention provides poliovirus like particles, which comprise stabilised empty poliovirus capsids that retain their native antigenic properties. The invention also provides methods of identifying mutations useful in the production of such poliovirus like particles, methods of producing such poliovirus like particles and the use of such poliovirus like particles in methods of vaccinating against poliovirus.